Table 5 Malaria case-management practices, by survey round
From: Monitoring health systems readiness and inpatient malaria case-management at Kenyan county hospitals
|  | Round 1 (N = 1162) | Round 2 (N = 1224) | p-value |
|---|---|---|---|
n (%) | n (%) | ||
Composite performance | 565 (48.6) | 689 (56.3) | 0.004 |
Malaria test done on admission | 1, 029 (88.6) | 1127 (92.1) | 0.080 |
Malaria test repeated | 53 (5.2) | 91 (8.1) | 0.034 |
Treatment for test positive severe cases | N = 405 | N = 465 |  |
|---|---|---|---|
Artesunate parenteral | 283 (69.9) | 366 (78.7) | 0.030 |
Quinine parenteral | 66 (16.3) | 54 (11.6) | 0.126 |
Artesunate and quinine parenteral | 35 (8.6) | 11 (2.4) | 0.003 |
artemether–lumefantrine | 16 (4.0) | 26 (5.6) | 0.245 |
Other anti-malarial treatmentsa | 2 (0.5) | 0 | 0.168 |
No anti-malarial treatment | 3 (0.7) | 8 (1.7) | 0.322 |
Treatment for test positive non-severe cases | N = 212 | N = 227 |  |
|---|---|---|---|
artemether–lumefantrine | 17 (8.0) | 20 (8.8) | 0.796 |
Artesunate parenteral | 133 (62.7) | 165 (72.7) | 0.053 |
Quinine parenteral | 40 (18.9) | 32 (14.1) | 0.316 |
Artesunate and quinine parenteral | 16 (7.6) | 3 (1.3) | 0.006 |
Other anti-malarial treatmentsb | 1 (0.5) | 3 (1.3) | 0.444 |
No anti-malarial treatment | 5 (2.4) | 4 (1.8) | 0.672 |
Treatment for test negative severe cases | N = 208 | N = 240 |  |
|---|---|---|---|
No anti-malarial treatment | 123 (59.1) | 149 (62.1) | 0.673 |
Artesunate parenteral | 58 (27.9) | 71 (29.6) | 0.783 |
Quinine parenteral | 14 (6.7) | 6 (2.5) | 0.128 |
Artesunate and quinine parenteral | 5 (2.4) | 1 (0.4) | 0.120 |
artemether–lumefantrine | 8 (3.8) | 12 (5.0) | 0.579 |
Other anti-malarial treatmentsc | 0 | 1 (0.4) | 0.328 |
Treatment for test negative non-severe cases | N = 204 | N = 195 |  |
|---|---|---|---|
No anti-malarial treatment | 140 (68.6) | 152 (78.0) | 0.063 |
Artesunate parenteral | 36 (17.7) | 29 (14.9) | 0.542 |
Quinine parenteral | 16 (7.8) | 7 (3.6) | 0.157 |
Artesunate and quinine parenteral | 3 (1.5) | 0 | 0.091 |
artemether–lumefantrine | 9 (4.4) | 7 (3.6) | 0.639 |
Treatment for not tested patients | N = 133 | N = 97 |  |
|---|---|---|---|
No anti-malarial treatment | 54 (40.6) | 29 (29.9) | 0.110 |
Artesunate parenteral | 45 (33.8) | 58 (59.8) | 0.002 |
Quinine parenteral | 23 (17.3) | 6 (6.2) | 0.037 |
artemether–lumefantrine | 10 (7.5) | 3 (3.1) | 0.147 |
Artesunate and quinine parenteral | 1 (0.8) | 1 (1.0) | 0.829 |